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Abstract
Protein aggregation and inclusion body formation are hallmarks of
neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and
amyotrophic lateral sclerosis (ALS). These neurodegenerative diseases share a common
pathology in that all include accumulation of insoluble protein aggregates in the brain.
TAR-DNA-binding protein (TDP-43) is the major component found in the pathological
inclusions of two of these diseases, ALS and frontotemporal lobar degeneration with
ubiquitin-positive inclusions (FTLD-U). This thesis focuses upon the biophysical basis
for TDP-43 aggregation in S. cerevisiae. Current in vitro evidence indicates that TDP-43
is a natively dimeric protein and that binding to RNA inhibits aggregation.
Corresponding genetic results in yeast in which specific components of the RNA-decay
machinery have been knocked-out, indicate that the buildup of specific cellular RNAs is
capable of counteracting TDP-43 aggregation and toxicity in vivo. This thesis provides
evidence of separate pathologies of TDP-43 and TDP-43 mutants in S. Cerevisiae. This
thesis also introduces preliminary data of the effect of in vitro synthesized RNA on TDP43 toxicity.
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Chapter One: Introduction
1.1 Overview: Protein Localization in Disease
Eukaryotic cells contain organelles and a complex endomembrane system. These
organelles provide distinct compartments for different metabolic activities. Protein
translation occurs solely in the cytosol compartment of the cell. Cells require
translocation of proteins to exert protein function in different organelles. Approximately
half of the proteins generated by a cell are transported into or across one or more cellular
membranes to reach their functional location (Chacinska et al. 2009).
Subcellular localization is essential to protein function. Using distinct
compartments provides a way to achieve functional diversity and save on protein design
and synthesis (Butler and Overall, 2009). Aggregation of amyloidogenic proteins can
result in the sequestration, inactivation, and irregular localization of numerous proteins.
Aberrantly localized proteins have been linked to human diseases as diverse as
amyotrophic lateral sclerosis, cancer, and Swyer syndrome (Winton et al., 2008; Dansen
and Burgering, 2008; McLane and Corbett, 2009). In patients with ALS, affected
neurons exhibit a prominent redistribution and nuclear inclusions of TAR DNA-binding
protein (TARDBP, also known as TDP43) or the protein fused in sarcoma (FUS) from
the nucleus to the cytoplasm (Neumann et al., 2006).
1

1.1.1 Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a late-onset neurodegenerative disease.
Characterization of the disease includes loss of motor neurons, progressive weakness, and
eventual paralysis leading to death by respiratory failure or pneumonia (Kierman et al.,
2011). ALS disease progression results in death within 3-5 years of diagnosis (Boillée et
al., 2006). Most ALS cases are sporadic, but 10% are familial. Approxamately 20% of
familial cases result from mutations in the SOD1 gene (encoding Cu/Zn superoxide
dismutase) and 34% from hexanucleotide repeat expansions in the chromosome 9 open
reading frame 72 gene (C9ORF72) repeats (Rosen et al., 1993; Blitterswijk et al., 2012).
SOD1 mutations are thought to cause disease by a toxic gain of function (Bruijn et al.,
1998), thus strategies to lower SOD1 levels are being pursued (Smith et al., 2006).
However, SOD1 mutations and C9ORF72 repeats account for only a small percentage of
ALS cases, and additional therapeutic strategies are needed. RNA-binding proteins and
RNA-processing pathways have recently been implicated in ALS and may provide
another possible therapeutic target (Lagier-Tourenne et al., 2010; Gitler et al. 2011).
1.1.2 TDP-43 aggregation in ALS
TDP-43 was identified as a major component of the ubiquitinated neuronal
cytoplasmic inclusions deposited in cortical neurons in FTD and in spinal motor neurons
in ALS (Neumann et al, 2006). TDP-43-positive inclusions have subsequently been
shown to be common in 97 % of ALS cases (Mackenzie, et al. 2007, Maekawa et al.,
2009), whether sporadic or familial. Additionally, mutations in the gene TARDBP,
2

which encodes TDP-43, have been identified in familial ALS and sporadic ALS cases
(Pesiridis et al., 2009; Rutherford et al., 2008; Sreedharan et al., 2008; Van Deerlin et al.,
2008; Yokoseki et al., 2008). Therefore, therapies targeting TDP-43 could be effective in
cases not caused by SOD1 mutation. Notably, TDP-43 inclusions occur in many
frontotemporal dementia cases. Targeting TDP-43 might be an effective therapeutic
strategy for these patients. Efforts are under way to define the mechanisms by which
TDP-43 and defects in RNA processing pathways contribute to ALS.
The exact cellular function of TDP-43 is officially unknown though experiments
show the protein plays a very important role in several biological systems. These
systems either regard the control of gene transcription, selected splicing processes, and in
the maintenance of mRNA stability.
Gene expression of HIV-1 is regulated by many host cellular factors. TDP-43
was found to inhibit the assembly of transcriptional factors in the regulatory system (Ou
et al., 1995). The binding site of TDP-43 was determined using band shift analysis. This
sequence was found to be the HIV-1 long terminal repeat known as TAR. The binding
section extends from nucleotide -18 to +80 and is important for the activation of gene
expression.
The mechanism of TDP-43 toxicity in ALS isn’t fully understood. Numerous
models exist. One model suggests TDP-43 undergoes nuclear export during times of
cellular stress. TDP-43 then moves to a stress granule or undergoes liquid-liquid phase
separation. Glycine rich C-terminal domain drives aggregation of TDP-43 causing
3

sequestering of vital RNAs and other RNA binding proteins (Figure 1). Various studies
have examined the roles of TDP-43’s gain or loss of function in disease. Overexpression
of wild-type TDP-43 recapitulates TDP-43 proteinopathy and disease phenotypes in an
array of animal models (Johnson et al., 2008; Wils et al., 2010; Li et al., 2010; Ash et al.,
2010). These results support a role for gain of toxic function in disease. Initial studies
testing a loss-of-function hypothesis used knock-out of TDP-43 from mice. The
complete knock-out of TDP-43 resulted in embryonic lethality (Wu et al., 2010; Sephton
et al., 2010; Kraemer et al., 2010). These early studies demonstrated TDP-43 plays a vital
role in early development without necessarily demonstrating that loss of function could
be degenerative in adulthood. To address these questions, conditional and partial
knockout models demonstrated loss of TDP-43 function can induce motor neuron defects,
a progressive motor phenotype reminiscent of human disease, and even typical TDP-43
proteinopathy (Wu et al., 2012; Iguchi et al., 2013; Kabashi et al., 2010). Interestingly,
either overexpression or knockdown of TDP-43 selectively in glia or muscle also
recapitulates ALS-like phenotypes (Yang et al., 2014; Diaper et al., 2013). The emerging
picture is that both gain and loss of TDP-43 function may be mechanistic in disease and
TDP-43 misfolding may link the two.
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Figure 1: Proposed model of aggregation in yeast. Cellular stress causes nuclear
export of TDP-43. TDP-43 moves into stress granule. Glycine rich C-terminal domain
drives aggregation of TDP-43 causing sequestering of vital RNAs and other RNA
binding proteins.

1.2 TDP-43
Human TDP-43 was first isolated in 1995. The discovery was made while
searching for novel transcriptional inactivators that bind the TAR DNA element of the
human immunodeficiency virus type 1 (HIV-1) virus. TDP-43 is a ubiquitously
expressed and highly conserved metazoan nuclear protein (Ayala et al., 2005). TDP-43
5

contains two RNA recognition motifs (RRMs) and a glycine-rich C-terminal domain.
TDP-43’s function is uncertain, but it likely plays important roles in pre-mRNA splicing
and transcriptional repression (Ayala et al., 2008; Buratti et al., 2001). The gene coding
for this protein (TARDBP) is present on Chromosome 1 and consists of 6 exons. Some
of these exons may be alternatively spliced to yield various isoforms of the protein
(Wang et al., 2004). TARDBP is a highly conserved gene throughout evolution and
relating homologues of human TDP-43 have been found in all higher eukaryotic species.
Homologues of TDP-43 were found in distant organisms such as Drosophila
melanogaster, Xenopus laevis, and Caenorhabditis elegans (Wang et al., 2004; Ayala et
al., 2005). Such a high degree of sequence conservation hints towards a fundamental role
played by this protein.
In ALS and frontotemporal lobar degeneration with ubiquitin-positive inclusions
(FTLD-U), TDP-43 is depleted from the nucleus and accumulates in ubiquitinated
cytoplasmic inclusions (Neumann et al., 2006). Notably, mutations in the TDP-43 gene
(TARDBP) are linked to sporadic and non-SOD1 familial ALS. This implies that TDP43 abnormalities are likely one cause of the disease (Kabashi et al., 2008; Sreedharan et
al., 2008; Van Deerlin et al., 2008; Rutherford et al., 2008; Gitcho et al., 2008; Yokoseki
et al., 2008).
1.2.1 TDP-43 Structure
Full open reading frame of TARDBP consists of 1,245 base pairs coding for 414
amino acids. The theoretical molecular weight of TDP-43 is 44,740 Daltons. TDP-43
6

contains two highly conserved RNA Recognition Motifs (RRM1 and RRM2) flanked by
an N-terminal and a C-terminal tail (Figure 2). This primary amino acid structure
resembles that of members of the heterogeneous ribonucleoprotein (hnRNP) family
(Krecic et al., 1999; Dreyfuss et al., 2002). The c-terminal tail contains a glycine-rich
region often found in proteins to mediate protein-protein interactions.
TDP-43 was found to natively dimerize in normal cells under physiological
conditions (Shilina et al., 2010). Formation of a monomer results in a more aggregation
prone protein.

Figure 2: Domain structure of TDP-43. Protein contains a N-terminal domain,
two RNA binding motifs, and a “prion-like” unstructured C-terminal domain.
1.2.2 TDP-43 Functions
Eukaryotic gene expression requires the coupling of many processes. These
processes include transcription, pre-mRNA processing, mRNA transport, and translation
(Maniatis et al, 2002; Proudfoot et al., 2002). Proteins that take part in these processes
are not confined to singular roles. The functions performed by TDP-43 seem to be
decided by the sequence specificity of the RRM domains. Previous research
demonstrated TDP-43 binds single stranded TG and UG repeats with high affinity via the
RRM1 domains (Ayala et al., 2005; Buratti et al., 2001). At least 5 repeated units (UG5)
7

are necessary for efficient binding of TDP-43 and efficiency increases with increased
length (Ayala et al., 2005).
Much less is known about the function of the N-terminal domain. The N-terminal
domain is loosely conserved compared to the RRM domains. The length of the Nterminal region varies in different species. The average of most species is 105 residues
compared to 174 residues in C. elegans. Contrary to the lack of conservation in length, a
striking example of conserved sequence exists in a 15-nucleotide region highly enriched
in acidic amino acids near the N-terminus of TDP-43 (Buratti et al., 2001).
1.2.3 TDP-43 is Intrinsically Aggregation Prone
In the absence of other components, TDP-43 spontaneously forms aggregates
bearing ultrastructural similarities to TDP-43 deposits in degenerating neurons of ALS
FTLD-U patients (Johnson et al., 2009). The C-terminal of TDP-43 was also found to be
important for aggregation. Truncation of the C-terminal led to a loss of toxicity and
aggregation (Johnson et al., 2009). Of the over 25 recently reported ALS- linked TDP-43
mutations, all but one mutation can be found within this domain (Banks et al., 2008).
Furthermore, similar aggregated C-terminal fragments accumulate in ALS and FTLD-U
(Neumann et al., 2006).
1.2.4 TDP-43 Liquid-Liquid Phase Separation
Stress granules are membrane-less assemblies generated by the condensation of
protein and nucleic acid components into liquid phases that self-segregate in the cell.
Like other ALS-associated RNA-binding proteins, TDP-43 has been shown to undergo
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liquid-liquid phase separation (LLPS) (Molliex et al., 2015). The N and C-termini of
TDP-43 can drive the phase separation (Schmidt et al., 2016). Three tryptophan residues
(Trp-334, Trp-385, and Trp-412) are the most important residues for TDP-43 LLPS.
These results also suggest that only a few residues might be required for TDP-43 LLPS
due the self-assembling tendency of the α-helical segment in the middle part of the Cterminal. This reduces the number of motifs required for formation of multiple binding
sites (Li et al., 2018). Furthermore, there’s evidence that disruption of LLPS increases
the pathological fibrilization of these ALS-associated RNA-binding proteins (Taylor et
al., 2017).
1.2.5 Mutations of TDP-43
Numerous mutations of TDP-43 have been found in patients with ALS. Testing
of these mutations in vivo and in vitro has yielded various results. ALS-associated TDP43 inclusions are primarily fragments. These fragments often include the entire CTD
(Neumann et al., 2006). The CTD is classified as “prion-like” due to a resemblance to the
amino acid frequency in yeast prion domains. This includes a low complexity
composition rich in polar while also and poor in aliphatic and charged residues (King et
al., 2012). The domain proves to be aggregation-prone in both in vitro and in vivo models
of ALS (Budini et al., 2015; Johnson et al., 2009; Wegorzewska et al., 2009).
Additionally, mutations in the CTD can have a profound effect on the behavior of the
domain. TDP-43 C-terminal domain liquid-liquid phase separation is mediated by
intermolecular interactions that include contacts involving the 321-340 region. ALS
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mutations (A321G, Q331K, and M337V) significantly disrupt phase separation
stimulating the conversion to aggregates. Some of these mutations result in a disruption
of the helical structure (possibly leading to an increase in aggregation) (Conicella et al.,
2016).
Native dimerization of TDP-43 occurs via the N-terminal domain interface. This
interface mainly occurs by way of hydrogen bonding and electrostatic forces between the
N-terminal domain and RRM domains of two TDP-43s. Mutation of serine to glutamic
acid at the 48th residue disrupts hydrogen bonding in the interface and weakens the
assembly of the dimeric state by removing the hydrogen bonding and electrostatic
interaction capabilities (Wang et al., 2018).
Mutations in the RRM1 have also been assessed. Mutating phenylalanine 147
and phyenylalanine 149 to leucines result in the inability of TDP-43 to bind RNA or
DNA (Buratti et al., 2001). TDP-43 can no longer bind DNA or RNA due to the loss of
pi-pi stacking interactions in the domain.
1.2.6 Enhancing TDP-43 Solubility Via RNA Binding
TDP-43 is a 414-amino acid nuclear protein composed of two highly conserved
RNA recognition motifs (RRM1 and RRM2) and a glycine rich C-terminal region. Both
RRMs are involved in binding of RNA/ DNA sequences enriched in UG or TG repeats.
Recent findings also suggest that RNA/DNA binding modulates TDP-43 solubility
(Pesiridis et al., 2011; Huang et al., 2013). These studies have shown that poly-TG
compounds can increase the solubility of refolded recombinant TDP-43 under
10

aggregation conditions induced by temperature (Huang et al., 2013). These experiments
provided evidence that inhibition of aggregation occurs by preservation of the protein’s
native dimeric state and prevention of a monomeric state. Additionally, poly-TG
compounds increase the solubility of TDP-43 greater than naturally occurring nucleotide
targets (Sun et al., 2014).

Length of TG/UG repeats and molar concentration of the

repeats also had an inverse relationship with Kd values (Bhardwai et al., 2013). These
discoveries provide a possible method of preventing TDP-43 aggregation using DNA or
RNA therapies. Increaseing the stability of RNAs in the cytoplasm may also play a role
in therapy effectiveness.
1.3 mRNA Structural Stability
Recent studies have revealed that long non-coding RNA (lncRNA) stability varies
widely (<0.5 h to >48 h). These findings hint at transcript half-life being one factor that
regulates biological function (Clark et al., 2012; Tani et al., 2012). Messenger RNA
(mRNA) degradation rates change in response to stimulus. This allows cells to quickly
increase or decrease mRNA abundance to meet a cell’s needs for specific proteins.
Collections of bound proteins and noncoding RNAs dictate mRNA degradation rates
through their ability to recruit (or exclude) the mRNA degradation machinery.
Deadenylation dependent mRNA decay is the major pathway in mammalian cells. One or
a combination of three deadenylases performs poly(A) tail removal. These particular
enzymes utilized appear to be mRNA specific (Garneau et al., 2007; Goldstrohm and
Wickens, 2008).
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Following deadenylation, degradation of a mRNA continues in a 5′ to 3′ or 3′ to 5′
direction. 3′ to 5′ decay of the mRNA body requires the 10 to 12 subunit exosome. This
contains RNase PH-domain enzymes, S1 and KH-family RNA-binding proteins, RNase
D-like enzymes, and RNA helicases (Mukherjee et al., 2002; Houseley et al., 2006).
When only a few 5′ nucleotides of the mRNA remain, the decapping enzyme DcpS
removes the 5’ cap structure (Liu et al., 2002). 5′ to 3′ mRNA decay begins with
decapping. Dcp1 and Dcp2 proteins come together to perform the decapping. Decapping
requires several other proteins including Lsm1–7 (bound at the 3′- end of the
deadenylated product), hEdc3, Rck/p54, and Hedls. Hedls enhances the decapping
activity of Dcp2 and promotes complex formation between Dcp1-Dcp2 (FengerGron et
al., 2005). Xrn1 degrades the mRNA following decapping.

Figure 3: Representations of 5’ and 3’ mRNA decay. Deadenylation One or a
combination of three deadenylases performs poly(A) tail removal. Following
deadenylation, degradation of a mRNA continues in a 5′ to 3′ or 3′ to 5′ direction. 5’ to
3’ decay proceeds with 5’ decapping by DCP1 and DCP2 followed by decay via XRN1.
3’ to 5’ decay proceeds with decay using a 3’ exosome until only a few nucleotides
remain. 5’ decapping then occurs via DcpS.
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1.3.1

XRN1-resistant RNA (xrRNA)

Flaviviruses are single-stranded positive-sense RNA viruses (Bhatt et al., 2013;
Mackenzie et al., 2004; Normile et al., 2013). The flavivirus genus includes, but is not
limited to, West Nile Virus, dengue virus, yellow fever virus, and Zika virus (Chambers
et al., 1990). Most of these viruses are transmitted by bite from an infected mosquito or
tick. During infection, not only is the viral genomic RNA (gRNA) replicated, but
specific 300–500 nucleotide-long subgenomic flaviviral RNAs (sfRNAs) also accumulate
from the incomplete degradation of the 3’ untranslated region (3’UTR) (Pijlman et al.,
2008). This incomplete degradation is performed by the 5’to 3’ host-cell exonuclease
Xrn1 (Jones et al., 2012). sfRNAs form from a halt in degradation at defined locations
within the gRNA’s 3’UTR (Pijlman et al., 2008).
Sequence alignment of xrRNA suggests a shared structure. Helices P1 and P2 of
the RNA stack coaxially while helix P3 is at an acute angle relative to P1 (Chapman et
al., 2014). This structure is consistent with other RNA three-way junctions from
flaviviruses (Lescoute et al., 2006). Together, helices P1 and P3 form a ring-like
structure. The continuous loop comprised of Nucleotides 33-49 resides entirely on one
side of the structure. The 5’end of the xrRNA passes through the center of the ring. Xrn1
encounters the compact and concave ring-like side of the xrRNA as it degrades the RNA
in a 5’ to 3’ direction (Chapman et al., 2014).
Upon encountering the concave ring-like structure, Xrn1 must pull the 5’ end of
the RNA through the ring. Unfolding this xrRNA requires Xrn1 to essentially turn the
13

structure inside out. During strand synthesis, the virally encoded RNA polymerase would
not encounter this impediment as it approachs from the 3’ end. This suggests the
characteristic of unidirectional resistance (Chapman et al., 2014).
1.3.2

3’ Expression and Nuclear Retention Element (ENE)

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is a highly
abundant, nuclear-localized lncRNA. MALAT1 is also a precurser for the tRNA-like
structures known as mascRNA. The structures are substrates for RNase P (Hutchinson et
al., 2007; Bernard et al., 2010; Stadler, 2010; Wilusz et al., 2008; Sunwoo et al., 2009).
The resulting 5′-cleavage products of MALAT1 end with a highly conserved sequence.
This sequence contains two U-rich motifs and a genomically encoded A-rich tract at the
3′ end (Wilusz et al., 2008; Sunwoo et al., 2009). In vitro decay assays have shown a
destabilization effect from mutations in the U-rich motifs and A-rich tract in mouse
MALAT1 RNA fragment. This result suggests the structure of this region contributes to
RNA stability despite the lack of a traditional poly(A) tail (Wilusz et al., 2008;
Guhaniyogi et al., 2001). This structure has U•A-U base triples flanked by two stems.
The 3′ sides of the U-rich internal loops can form 11 consecutive Watson–Crick base
pairs with the downstream A-rich tract, and the 5′ sides are proposed to engage in
Hoogsteen interactions. Analyses of the MALAT1 ENE revealed that stabilization
activity requires an intact triple helix, strong stems at the duplex-triplex junctions, a G-C
base pair flanking the triplex to mediate potential A-minor interactions, and the 3′-
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terminal A of the A-rich tract to form a blunt-ended triplex lacking unpaired nucleotides
at the duplex- triplex junction (Brown et al., 2012)
1.4 Saccharomyces cerevisiae Genomics
The budding yeast, Saccharomyces cerevisiae (S. cerevisiae), serves as an
important experimental organism for revealing gene function. In addition to carrying out
all the basic functions of eukaryotic cells, up to 30% of positionally-cloned genes
implicated in human disease have yeast homologs (Bassett et al., 1997). S. Cerevisiae are
also utilized because of the ease with which it can be manipulated. For these reasons, S.
cerevisiae research serves as a model organism for a variety of processes that occur in
humans.
The Gateway® cloning method for use in S. cerevisiae was developed to address
the time-consuming nature of standard cloning methods. The system adapted the pRS
series of yeast shuttle vectors. These vectors are based on the site-specific recombination
properties of the bacteriophage lambda (Landy, 1989). The lambda recombination
system requires two major components: DNA recombination sites and enzymes to
facilitate the recombination reaction. A mixture of enzymes that bind to specific
sequences catalyzes the recombination. The enzymes bring together the target sites,
cleave them, and covalently attach the DNA. Recombination occurs following two pairs
of strand exchanges and ligation of the DNAs in a novel form. The recombination
proteins involved in the reaction differ depending upon whether lambda utilizes the lytic
or lysogenic pathway. The lysogenic pathway is catalyzed by the bacteriophage λ
15

Integrase (Int) and E. coli Integration Host Factor (IHF) proteins (BP ClonaseTM enzyme
mix). The bacteriophage λ Int and Excisionase (Xis) proteins, and the E. coli Integration
Host Factor (IHF) protein catalyze the lytic pathway (LR Closest enzyme mix) (Landy,
1989; Ptashne, 1992).

Figure 4: Gateway Clonase reactions: BP reactions follow the Lysogenic pathway.
LR reactions follow the Lyctic pathway. Each pathway uses a unique set of enzymes to
accomplish the recombination reaction.
ORFs are first moved from a PCR product or entry clone to a donor vector. At this
stage, ORFs are flanked by attB sites. The attB sites on the ORF react with the attP sites
on a donor vector. This BP reaction results in the ORF in a donor vector with attL sites.
The new donor vector is then moved from the donor vector to a destination vector. This
stage utilizes the attL sites on the donor vector and attR sites on the destination vector.
This LR reaction results in the ORF in a destination vector with attB sites.
288 yeast Gateway® vectors were developed using two commonly used GPD and
GAL1 promoter expression systems. Using these systems enable expression of ORFs
either constitutively or under galactose-inducible conditions. The expression system also
enables proteins of interest to be fused to a choice of frequently used N- or C-terminal
tags. These tags include EGFP, ECFP, EYFP, Cerulean, monomeric DsRed, HA or TAP.
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Figure 5: Gateway Destination Vector. 2µ ori: fragment from the 2 micron circle (a
natural yeast plasmid) allows for 50+ copies to stably propogate per cell.. AmpR: coding
sequence gives E coli containing the plasmid ampicillan resistance. attR1 and attR2 sites
for site specific recombination. ccdB gene: bacterial toxin that poisons DNA gyrase for
selection of successful LR products. DsRed Monomer: C-terminal DsRed fluorescent
tag.
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1.4.1 Using Yeast as a TDP-43 Proteinopathy Model
TDP-43 toxicity and aggregation were reported using yeast (Johnson et al., 2008).
This model recapitulates numerous distinctive cellular features of human TDP-43
pathology, including conversion from nuclear localization to cytoplasmic aggregation.
The pathological features of TDP-43 are distinct from those of other protein-misfolding
diseases in yeast models (Johnson et al., 2008). This suggests that rather than general
cellular stresses associated with accumulating misfolded proteins, the yeast model reveals
specific aspects of the underlying biology of the disease associated with TDP-43
aggregation. This work provided framework for investigating the toxicity of TDP-43
aggregation relevant to human disease while also establishing a manipulable model for
discovering potential therapeutic strategies (Johnson et al., 2008).
The manipulability of yeast provided the ability to perform a genome-wide screen
to identify genes that modify TDP-43 toxicity (Giaever et al., 2002). Deletion of the
lariot debranching enzyme (dbr1) provided the most potent suppressor of TDP-43
toxicity (Armakola et al., 2012). dbr1 catalyzes the debranching of lariat introns that are
formed during pre-mRNA splicing. In yeast, it was shown that inhibiting the
debranching enzymatic activity of dbr1 sufficiently rescued TDP-43 toxicity (Armakola
et al., 2012). Evidence was also provided that intronic lariat species that accumulate in
the cytoplasm of dbr1∆ cells act as decoys to sequester toxic cytoplasmic TDP-43
(Armakola et al., 2012). This possibly prevents aggregated TDP-43 from interfering with
other essential cellular RNA targets and RNA-binding proteins. Knockdown of dbr1 in a
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human neuronal cell line and in primary rat neurons is also sufficient to rescue TDP-43
toxicity, suggesting that the effect of dbr1 on TDP-43 toxicity is conserved from yeast to
mammals (Armakola et al., 2012).
1.5 RNA Aptamers
Nucleic acids were once only considered as the key molecules solely involved in
storage and expression of genetic information. That narrow outlook changed after the
discovery of non-coding RNAs. These RNAs exploit the structural characteristics of
nucleic acids to execute a variety of functions. These functions include gene regulation,
catalysis, and specific ligand binding (McKeague et al., 2012). Following this discovery,
a new class of synthetic nucleic acid molecules called “Aptamers” developed. These are
small single stranded DNAs or RNAs. These DNAs and RNAs range from 15 to 150
nucleotides with an ideal length of 20-40 nucleotides (Wang et al., 2012). These DNAs
and RNAs fold into a well-defined three–dimensional structure. These structures allow
binding to target ligands with high affinity and specificity (Mayer, 2009; Tuerk et al.,
1990).
1.5.1 MS2 System
Aptamers have been developed to visualize RNA in vivo. In 1998, a method was
introduced to visualize mRNA dynamics in live cells using an MS2-GFP coat protein.
The system utilizes bacteriophage MS2 operator hairpin and coat protein. The coat
protein selectively binds to the operator hairpin allowing for specific labeling (Bertrand et
al., 1998).
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In this system, the sequence of aptamers (MS2 Hairpins) that recognize the MS2
coat protein is added to the untranslated region of the target RNA. The cells are
transfected with this construct and the expression construct for the MS2 coat protein
fused to GFP. Expression of the tagged RNA can now be visualized via the bound MS2GFP protein. Applying this technique has enabled several insights into the process of
mRNA trafficking.
1.5.2 Spinach Aptamer
Protein based imaging systems are useful for tracking and imaging RNA, but their
applications are limited by high background from the unbound protein. To avoid these
limitations, fluorophore molecules have been developed and aptamers were designed
against these fluorophores. Specification of these small molecules require them to be
non-toxic, easily permeable, and provide low non-specific binding to cellular
components. Fluorophores have been designed to provide all the above criteria and
provide a low fluorescence in the free state and provide fluorescence increases upon
binding to their specific aptamer. Malachite green is one such fluorophore. The
intramolecular motions are restricted upon aptamer binding. This binding and
conformation restriction leads to ~2360 times increase in fluorescence (Babendure et al.,
2003). When the Hoechst 1c (Sando et al., 2008) small molecule binds with nanomolar
affinity, their fluorescence increases 50-60 fold. Recently, a GFP fluorophore analog, 3,5difluoro-4- hydroxybenzylidene imidazolinone (DFHBI), was discovered. This small
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molecule becomes fluorescent when it binds to an RNA aptamer known as Spinach
(Paige et al., 2011).
The spinach aptamer has been utilized to image highly abundant RNA like the 5S
rRNA in bacterial and mammalian cells and has been applied as a sensor to image
intracellular metabolites (Paige et al., 2012). DFHBI also provided a means to visualize
the ASH1 gene is S. cerevisiae validating this technology in yeast (Guet et al., 2015).
Binding of DFHBI to the RNA promotes stabilization of the transducer stem enabling the
Spinach RNA to fold and bind DFHBI. Binding of DFHBI to the spinach RNA then
causes fluoresces of the small molecule, limiting the background.
1.6 Research Aim
TDP-43 was recently found as the major protein in ubiquitinated inclusions in
ALS (Neumann et al., 2006). When TDP-43 toxicity is tested in dbr1 deleted yeast, the
build-up of lariats proves to rescue tdp-43 toxicity by acting as a decoy. Taking the
knowledge of bound RNA to TDP-43 stabilized dimerization, TDP-43 toxicity could be
rescued by synthetic RNAs. The main aims of this thesis are:
•

To demonstrate different aggregation properties of wild type TDP-43 and mutant
TDP-43.

•

To demonstrate a difference in wild type TDP-43 and mutant TDP-43 toxicity in
S. cerevisiae.

•

To present evidence from yeast spotting assays and confocal microscopy showing
how in vitro synthesized RNAs affect TDP-43 toxicity in yeast.
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Chapter Two: Materials And Methods
2.1 Yeast Strains, Media, and Plasmids
Yeast were obtained from GE Dharmacon. Yeast parental strain BY4730 (catalog
# YSC1061) were used for experiments. Yeast cells were grown in rich yeast peptone
dextrose media (YPD) or in synthetic media lacking leucine and containing 2% glucose
(SD/-Leu), raffinose (SRaf/-Leu), or galactose (SGal/-Leu). 1 liter of YPD was prepared
by adding 20 g yeast extract and 10 g peptone to 900 mL H2O. The solution is then
autoclaved for 30 minutes. 100 mL 20% dextrose is then added to the solution before
use.
Yeast containing a deletion of the lariat debranching enzyme dbr1 were obtained
from Dharmacon, Inc. (catalog number YSC6273-201926517). Deletion of dbr1 was
further selected for on plates containing YPD+G418 (200 µg/mL). When plasmids
containing auxotrophic markers were transformed into dbr1Δ cells, cells were selected
for on plates containing
A Yeast Gateway Kit (Kit # 1000000011) was obtained from Addgene. The kit
containing 285 yeast Gateway destination vectors based on a widely used pRS series of
yeast shuttle vectors and contained two commonly used GPD and GAL1 promoter
expression systems.
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To generate C-terminally DsRed-tagged or GFP-tagged TDP-43 constructs, a
PCR protocol was used to amplify TDP-43 without a stop codon and incorporate the
Gateway attB1 and attB2 sites. AttB1 and a primer consisting attB2 plus the 3’ end of
TDP-43 (omitting the stop codon). Q5® High-Fidelity DNA Polymerase was used to
perform the site directed mutagenesis. The resulting PCR products were purified using
the Zymo Research DNA Clean & Concentrator.
AttB1

5’GGGGACAAGTTTGTACAAAAAAGCAGGCT3’

attB2+3’TDP43

5’ACCACTTTGTACAAGAAAGCTGGGTTCATTCCCCAGCCAGAAGAC3’

To generate a C-terminally DsRed-tagged or GFP-tagged TDP-43 mutant
constructs (Figure 9), a PCR protocol was used to amplify the previously described TDP43 with the desired mutation. One TDP-43 mutant was generated by deleting amino
acids 307-414. This C-terminal domain deleted (ΔCTD) mutant proved does not
aggregate but still contains RRM1 and RRM2 for binding of RNA/DNA (Johnson et
al.,2007). Johnson also found the mutant to be non-toxic in yeast. AttB1 and a primer
consisting attB2 plus the coding sequence for amino acids 408-414. Q5® High-Fidelity
DNA Polymerase was used to perform the site directed mutagenesis. The resulting PCR
products were purified using the Zymo Research DNA Clean & Concentrator.
attB1

5’GGGGACAAGTTTGTACAAAAAAGCAGGCT3’

attB2+3’TDP43

5’ACCACTTTGTACAAGAAAGCTGGGTATTACTACCTTGATTGTT3’

To generate a negative control containing a C-terminal fluorescent protein, a PCR
protocol was used to generate the coding sequence for the first 6 amino acids from yeast
GAPDH. One primer containing the sequence for attB1 and the first 15 amino acids of
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GAPDH. The other primer contained the sequence of attB2 and the first 17 amino acids
of GAPDH. The first 15 nucleic acids of primer 1 are the reverse compliment of last 15
nucleic acids of primer 2. PCR was used to anneal the primers.
attB1+5’GAPDH

5’GGGGCAAGTTTGTACAAAAAAGCAGGCTATGATCAGAATTGCT3’

attB2+3’GAPDH

5’GGGGACCACTTTGTACAAGAAAGCTGGGTTAATAGCAATTCTGATCAT3’

The 76 base-pair PCR product (GAPDH segment) was purified by a phenolchloroform extraction followed by an ethanol precipitation. An equal volume of
25:24:1(v/v/v) phenol/chloroform/isoamyl alcohol was added to the PCR product. The
mixture was mixed using a vortex for 30 seconds before being centrifuged for 30
seconds. The aqueous phase was carefully removed by pipette and transferred to a new
tube. 3M Sodium acetate was added to the PCR product (final concentration of 0.3M
sodium acetate). 2.5 volumes of ice-cold 100% ethanol was then added to the mixture.
The solution was then placed at -80oC for at least 15 minutes. The solution was then
centrifuged in a fixed angle microcentrifuge at 21,330 RCF for 5 minutes. The
supernatant was then removed before1 mL of 70% ethanol was added to the pellet. The
tube was mixed by inversion before being centrifuged at 21,330 RCF for 5 minutes in a
fixed angle microcentrifuge. The pellet was dried before being resuspended in molecular
biology grade H2O.
Resulting PCR products were shuttled into pDONR221 using a Gateway BP
reaction. The BP reaction resulted in pDONR221 containing TDP-43 flanked with attL1
and attL2. Each BP reaction contained: 150 ng PCR product, 150 ng Pdonr221, TE
buffer (to 4 µL), and 1 µL BP Clonase II Mix (ThermoFisher catalog # 11789020).
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A Gateway LR reaction was the used to shuttle TDP-43 into the Gatewaycompatible yeast expression vectors pAG425GAL-ccdB-DsRed (Figure 8) and
pAG425GAL-ccdB-eGFP. The fused DsRed fluorescent protein acts a true monomer.
This generation of DsRed accomplishes proper localization and a quicker maturation
half-life of 40 minutes—improvements on previous tetrameric DsRed proteins which
colocalized and had a maturation half-life of 12 hours (Strongin et al., 2007). Each LR
reaction contained: 150 ng PCR product, 150 ng destination vector, TE buffer (to 4 µL),
and 1 µL LR Clonase II Mix (ThermoFisher catalog #11791100).
To generate constitutively active RNA decoys (Figure 7A), custom DNA flanked
by the Gateway attB1 and attB2 was obtained from Integrated DNA Technologies. The
open reading frame consisted of two Dengue Virus xrRNA structures, RNA binding
domain (Figure 6), spinach aptamer, MS2 hairpins, 3’ ENE, and Civ1.2Rz ribozyme.
The designed DNA sequences were shuttled into pDONR221 using a Gateway BP
reaction. The BP reaction resulted in pDONR221 containing the custom DNA flanked
with attL1 and attL2. A Gateway LR reaction was the used to shuttle custom DNA into
the Gateway-compatible yeast expression vectors pAG423GPD-ccdB (Figure 8).
Gateway Vector
TGGTTGGCCA CACACTTACT TTGGGCGTGG CACACTTACA GGGTTTCGTA CACACTAACT GGTTCTCGAT
JPS_1481 Vector GTGTGAATGAAT ACACACTTACT GTGTGAATGAAT CCACACTTACT GTGTGAATGAAT TCACACTTACT GTGTGAATGAAT

Figure 6: Sequences for binding domains used for RNA decoys. UG rich sequences
shown in bold.
RNA decoys were also tested in plasmids previously used to test xrRNA stability
(Figure 7B). Two BglII sites were used to remove the previous insert by a single
digestion of the backbone. 3 inserts were designed: one insert contained two consecutive
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xrRNAs, 12 TG repeat binding domains (Figure 6), a spinach RNA aptamer, and a
Cricket paralysis virus IRES. One insert contained two consecutive xrRNAs, a spinach
RNA aptamer, and a Cricket paralysis virus IRES. The last insert contained two
consecutive mutated xrRNAs (First three nucleotides in the pseudoknot GTCàCAG), 12
TG repeat binding domains, a spinach RNA aptamer, and a Cricket paralysis virus IRES.
All 3 inserts are flanked by BglII digest sites to allow ligation with the backbone.

A

B

LacZ

Figure 7: RNA decoy designs used in yeast. A. Decoy used in the Gateway system.
B. Decoy used in the JPS-1481 system. Both designs contain a decay resistant structure,
TDP-43 binding site, and aptamer for RNA labeling.
Transformations were performed to obtain yeast containing the generated
constructs. Plasmid DNA was transformed using the PEG/lithium acetate method. Yeast
were grown to mid-log phase. Yeast were then washed with qH2O before being
resuspended in 100 mM lithium acetate.

Finally, yeast cells were resuspended in 50 µL

per transformation qH2O. For each transformation, 50 µL cells were combined with
10µL ssDNA, 1µg DNA, and 500 µL PLATE (40% PEG 3350, 100mM LiOAc, 10 mM
TRIS 7.5, and 0.04 mM EDTA). Mixture was heated to 42oC for 40 minutes on a heating
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Figure 8: Overview of cloning used to obtain expression vectors. PCR product
flanked by attB sites reacts with entry vector with attP sites in a lysogenic (BP) reaction.
Resulting product (with attL sites) then reacts with destination vector (attR sites) in a
lyctic reaction to produce the expression vector with attB sites.
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block. Cells were then plated on a selection media plate depending on the auxotrophic
marker. Plates were placed in an incubator for at least 24 hours at 30oC. Culture was
then taken and struck on a selection media plate for single colonies.

1. Q331k

2. S48E

4. C-terminal
truncation
(at amino
acid 306)

3. Two separate
phenylalanine to
Leucine substitutions

Figure 9: Location of each mutation made and tested. 1. Lysine to glutamine
substitution at residue 331 2. Serine to glutamic acid at the 48th residue. 3. Two separate
phenylalanine to leucine substitutions. 4. C-terminal truncation at amino acid 306.
2.2 Yeast Spotting Assays
To measure cell viability, yeast-spotting assays were performed. Yeast cells were
grown overnight at 30°C in synthetic liquid media lacking leucine and containing glucose
(Glu/-Leu). 5 mL of fresh SD media were then seeded from the overnight culture (100
µL of overnight culture into 5 mL fresh media) and grown at 30°C until they reached log
or mid-log phase. Culture ODs were then normalized, serially diluted in a 96 well plate,
and spotted onto synthetic solid media containing glucose or galactose lacking leucine
using a V&P Scientific 48 pin Multi-Blot Replicator (cat# VP407AH). The plates were
then grown at 30°C for 2–3 days. Pictures were then taken using a ChemiDoc™ MP
Imaging System.
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2.3 Confocal Microscopy
To visualize TDP-43 aggregates, yeast cells were grown overnight at 30°C in
synthetic liquid media lacking leucine and containing raffinose (SRaf/-Leu) until they
reached log or mid-log phase. Cells were then spun down at 3426 rcf, resuspended in
synthetic media containing glucose or galactose lacking leucine, then incubated at 30°C
for 4 or 18 hours. Cells were then fixed using 3.7% formaldehyde for 15 minutes. After
fixation, cells were washed twice using phosphate buffered saline. Cells were then
permeabilized using 0.1% triton-x for 7 minutes. After permeabilization, cells were
washed twice using phosphate buffered saline. Final resuspension of the cells was done
in 200 µL PBS. 1 µL of the cell suspension was then combined with 5 µL DAPI
mounting media. Cells were cover slipped, sealed with nail polish, and placed in a light
protective slide holder. Slides were then imaged on an Olympus FV3000 Confocal Laser
Scanning Microscope using a 100x objective. DAPI laser conditions were set at 1% laser
power, 700V, 1.0X gain, and 3% offset. Ds-Red laser conditions were set at 0.5% laser
power, 510 V, 1.0X gain, and 3% offset.
2.4 Live Cell Imaging
Live cells were imaged to visualize RNA decoys and perform fluorescence
recovery after photobleaching (FRAP). Yeast cells were grown overnight at 30°C in
synthetic liquid media lacking leucine and containing raffinose (SRaf/-Leu) until they
reached log or mid-log phase. 20% glucose or galactose was then added to the cultures to
reach a final concentration of 2%. Cultures were then placed back at 30°C for 3.5 hours.
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DAPI was then added at a final concentration of 2.5 µg/mL and cultures were placed
back at 30°C for 30 minutes. 100 µL cell suspension added to wells coated in
concanavalin A. 1 µL of 10 mM DFHBI was thenadded to wells. The plate was then left
at 30oC for 20 minutes before removing the top liquid from wells. Wells were then
washed with SD media containing 100 µM DFHBI. 100 µL fresh SD media containing
100 µM DFHBI added to wells before imaging. Cells imaged on an Olympus FV3000
Confocal Laser Scanning Microscope using a 100x objective. Ds-Red laser conditions
were set at 0.5% laser power, 510 V, 1.0X gain, and 3% offset.
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Chapter Three: Results
3.1 Wild Type TDP-43 Toxicity versus TDP-43 mutants
To identify toxicity differences between wild type TDP-43 and mutants of TDP43, yeast-spotting assays were performed on wild type yeast containing plasmids coding
for C-terminally DsRed tagged TDP-43 or a mutant TDP-43 on a galactose promoter. To
ensure the DsRed fluorescent protein didn’t have a toxic effect on the yeast, the first 6
amino acids of yeast GAPDH were linked to the DsRed fluorescent protein on the Cterminal. Yeast were serially spotted on an auxotrophic selective plate containing
glucose (expression off) or galactose (expression on). Spotting on a glucose plate ensured
consistent spotting between all test groups and a baseline for no toxicity.
Yeast containing expression plasmids coding for DsRed showed viability equal to
yeast on the glucose plate (expression off). TDP-43 showed high levels of toxicity
compared to yeast containing plasmids coding for DsRed. Yeast expressing Q331K or
S48E showed equal levels of toxicity compared to yeast containing plasmids coding for
TDP-43. RRM mutant showed cell viability equal to yeast containing DsRed
plasmids. ΔCTD showed lower levels of toxicity compared to TDP-43. Cells still
showed lessened cell viability compared to no expression (Figure 10).
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Figure 10: Yeast spotting assay comparing wild type TDP-43 to varous mutants of
TDP-43. Fivefold serial dilution of yeast cells spotted onto glucose (TDP-43 off) or
galactose (TDP-43 on).

3.2 TDP-43 and TDP-43 mutant Toxicity in Wild-Type and dbr1Δ Yeast
To identify wild type and mutant TDP-43 toxicity differences in wild type and
dbr1Δ yeast, yeast-spotting assays were performed with wild type and dbr1Δ yeast
containing plasmids coding for C-terminally DsRed tagged TDP-43 or a mutant TDP-43
on a galactose promoter. Deletion of the dbr1 gene previously showed rescue
capabilities from TDP-43 toxicity (Johnson et al., 2012). dbr1Δ expresses the lariat
debranching enzyme which takes part in intron turnover. Without the lariat debranching
enzyme, cells can no longer debranch lariats during pre-mRNA splicing. Intronic lariat
species accumulate in the cytoplasm of dbr1∆ cells and act as decoys to sequester toxic
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cytoplasmic TDP-43, possibly preventing it from interfering with other essential cellular
RNA targets and RNA-binding proteins.
Yeast containing expression plasmids coding for DsRed showed viability equal to
yeast on the glucose plate (expression off) in both wild type and dbr1Δ cells. As
previously demonstrated, dbr1Δ cells showed rescue of TDP-43 toxicity compared to
wild type yeast. dbr1Δ cells also showed rescue of Q331k toxicity compared to wild type
yeast. Cells containing RRM mutant showed cell viability equal to yeast containing
DsRed plasmids in both wild type and dbr1Δ. ΔCTD showed lower levels of toxicity
compared to TDP-43 in both wild type and dbr1Δ cells. Complete rescue of ΔCTD
toxicity was seen in dbr1Δ cells (Figure 11).
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Figure 11: Yeast spotting assay comparing wild type TDP-43 to varous mutants of
TDP-43 in wild type and dbr1Δ yeast
3.3 Wild Type TDP-43 Aggregation versus TDP-43 mutants
To identify aggregation differences between wild type TDP-43 and mutants of
TDP-43, wild type yeast containing plasmids coding for C-terminally DsRed tagged
TDP-43 or a mutant TDP-43 on a galactose promoter were observed using a confocal
microscope. To ensure the DsRed fluorescent protein didn’t aggregate, a construct
containing the first 6 amino acids of GAPDH with a C-terminal DsRed tag was also
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tested. Yeast were grown to mid-log phase before being resuspended in SD media
containing glucose (expression off) or galactose (expression on). Cultures were then
grown for 4 or 18 hours before being fixed and permeabilized. 1 µL of cell suspension
was added to 5 µL of DAPI mounting media. Cover slides were added and sealed with
nail polish. Negative control samples (left in glucose) were used to find appropriate
threshold values when preparing images (Figure 12). A sum was taken of all z-stacks in
each image. A lower contrast level of 500 relative fluorescent units for the DsRed
channel was found appropriate for negative controls. This lower threshold was then used
for all images.
After 4-hour induction, wild type TDP-43 and Q331K show cytoplasmic
inclusions when highly expressed in the cell. Wild type TDP-43 show fewer puncta per
cell compared to Q331K (Figure 13). 18-hour inductions of Q331K result in fewer, but
larger, cytoplasmic inclusions. Wild type TDP-43 inclusions after an 18-hour induction
are more similar in aggregation tendacies to Q331K after a 4-hour induction (Figure 14).
Cells containing RRM mutant expression plasmids display a very unusual
localization. Aggregates form bright, round cytoplasmic structures. Increasing induction
time from 4 to 18 hours results in an increase in inclusion size. Cells often contain a
single inclusion (Figure 13 and 14).
S48E and ΔCTD showed similar nuclear localization after a 4-hour induction.
Cells expressing protein show overlap of DsRed and DAPI staining. Cytoplasmic TDP43 remains diffuse (Figure 13). 18-hour images of S48E show a single, large aggregate
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overlapping, but larger in size, with the nucleus. 18-hour images of ΔCTD still show
diffuse cytoplasmic protein with nuclear localization (Figure 14).
3.4 TDP-43 and TDP-43 mutant Aggregation in Wild-Type and dbr1Δ Yeast
To identify wild type and mutant TDP-43 aggregation differences in wild type
and dbr1Δ yeast, wild type and dbr1Δ yeast containing plasmids coding for C-terminally
DsRed tagged TDP-43 or a mutant TDP-43 on a galactose promoter were observed using
a confocal microscope. Deletion of the dbr1 gene previously showed prevention of
multiple, irregular shaped aggregates (Johnson et al., 2012). Aggregates instead formed
round singular cytoplasmic inclusions.
After a 4-hour induction, cells containing TDP-43 and Q331K agree with the
previous findings in dbr1Δ yeast. Singular round cytoplasmic inclusions are oberserved.
Cells containing S48E, RRM mut, and ΔCTD show no differences between wild type and
dbr1Δ yeast after a 4-hour induction (Figure 15 and 16).
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Figure 12: Yeast containing DsRed on a galactose promotor. 1. Unstimulated cultures
before and after contrast adjustment. Background is effectively removed after lower
contrast was set to 500. 2. Stimulated cultures before and after contrast adjustment.
Yeast still show high levels of diffuse DsRed after adjustment.
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ΔCTD

Figure 13: Confocal imaging comparing wild type TDP-43 to
varous mutants of TDP-43 in wild type yeast after 4 hours of
induction in media containing galactose
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Figure 14: Confocal imaging comparing wild type TDP-43 to
varous mutants of TDP-43 in wild type yeast after 18 hours of
induction in media containing galactose.
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Figure 15: Confocal imaging comparing wild type TDP-43 to
varous mutants of TDP-43 in dbr1Δ yeast after 4 hours of induction in
media containing galactose.
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Figure 16: Confocal imaging comparing wild type TDP-43 to
varous mutants of TDP-43 in dbr1Δ yeast after 18 hours of induction
in media containing galactose.
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3.5 Wild Type and RRM Mutant FRAP
RRM mutant and wild type aggregates were photobleached to observe the
dynamics of the inclusion. Aggregates only partly recovered by time=50 seconds (46
seconds after photobleaching. Over the 46 seconds, the RRM mutant aggregate
recovered to a larger extent compared to the wild type aggregate (Figure 17). Recovery
of fluorescents proves diffusion of labeled TDP-43 and a dynamic state of the inclusion.
Wild Type

Time=0 sec

Time=4 sec

Time=50 sec

Time=0 sec

Time=4 sec

Time=50 sec

RRM Mut

Figure 17: Different timepoints of FRAP experiment. Photobleacing
occurred at time=4 seconds.
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3.6 Wild Type TDP-43 Aggregation With TDP-43 Decoys
To identify the effects of synthetic RNA on cell viability in yeast containing TDP43, yeast-spotting assays were performed on wild type yeast containing plasmids coding
for C-terminally DsRed tagged TDP-43 on a galactose promoter and constitutively active
plasmids coding for the synthetic RNA. Cells were tested 3 different synthetic RNAs.
The RNAs differed in number of TDP-43 binding domains (UG rich sequences). RNAs
contained 1, 5, or 10 binding domains. To ensure the DsRed fluorescent protein didn’t
have a toxic effect on the yeast, the first 6 amino acids of yeast GAPDH were linked to
the DsRed fluorescent protein on the C-terminal. Yeast were serially spotted on an
auxotrophic selective plate containing glucose (expression off) or galactose (expression
on). Spotting on a glucose plate ensured consistent spotting between all test groups and a
baseline for no toxicity. Spotting on a glucose plate also ensure that adding transcription
of synthetic RNAs to the yeast doesn’t reduce cell viability.
Yeast containing expression plasmids coding for DsRed and empty destination
vector showed viability equal to yeast on the glucose plate (expression off). TDP-43 and
empty destination vector showed high levels of toxicity compared to yeast containing
plasmids coding for DsRed and empty destination vector. Yeast expressing TDP-43
with X2DSH2E and X2D10SH2E showed equal levels of viability compared to yeast
containing plasmids coding for TDP-43 and empty destination vector (Figure 18).
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Emp 425Gal+Emp 423GPD
GAPDH+Emp 423GPD
TDP43+Emp 423GPD
TDP43+X2DSH2E
TDP43+X2D5SH2E
TDP43+X2D10SH2E

Glucose

Galactose

(Expression Off)

(Expression On)

Figure 18: Yeast spotting assay comparing yeast containing TDP-43 with and
without syntheticly designed RNA decoys. Fivefold serial dilution of yeast cells spotted
onto glucose (TDP-43 off) or galactose (TDP-43 on).
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Chapter Four: Conclusions
4.1 Thesis Summary
TDP-43 aggregation and cytoplasmic inclusion are hallmarks of non-familial
ALS. Distinct pathologies present when mutations of TDP-43 are overexpressed in S.
cerevisiae. Disruption of the RRM1 by two phenylalanine mutations prevents the ability
of TDP-43 to bind RNA by eliminating the ability to form pi-pi stacking in the RRM1
domain (Buratti et al., 2001). Imaging of RRM shows the mutant still aggregates when
overexpressed, but yeast spotting assays present evidence the mutation now renders the
protein non-toxic. These findings suggest binding and sequestering of RNAs in the cell
result in a loss of cell viability.
The C-terminal domain of TDP-43 proves to be important for protein aggregation.
Two different mutations in the C-terminal domain were tested. One mutation, Q331K
(lysine to glutamine substitution at residue 331), disrupts the alpha helix in the Cterminal. This disruption of the alpha helix significantly disrupts phase separation—
stimulating the conversion to aggregates (Conicella et al., 2016). Confocal imaging of
Q331K shows more cytoplasmic inclusions per cell compared to wild-type TDP-43 after
4-hour induction. After an 18-hour induction, Q331K inclusions are larger in size than
wild type TDP-43. An increased proclivity to aggregate doesn’t result in decreased cell
viability in yeast spotting assays. Overexpression of both Q331K and wild type TDP-43
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show similar levels of toxicity. This result possibly stems from reaching the upper
threshold of cytotoxicity. Both wild type TDP-43 and Q331K show almost complete
elimination of cell viability. Yeast spotting assays performed with yeast containg wild
type TDP-43 and Q331K on low copy plasmids might provide more insight on toxicity
differences.
Deletion of the C-terminal domain removes the “prion-like” properties of TDP-43
while leaving the RNA binding ability and selectivity domain alone. The truncation
answers an interesting question about the structural influence of TDP-43’s toxicity in
yeast. Confocal imaging shows a decreased propensity to aggregate. Yeast spotting
assays show a decreased toxicity compared to wild-type TDP-43. Aggregation of the
protein proves to be an important aspect of the toxicity of TDP-43. Some loss of cell
viability was seen in yeast containing the ΔCTD mutant (possibly indicating soluble
protein bound to RNA in the cytoplasm still reduces cell viability).
The N-terminal domain of TDP-43 creates the interface in the native dimeric
state. Hydrogen bonding and electrostatic forces hold this dimeric state together.
Mutation of serine to glutamic acid at the 48th residue disrupts hydrogen bonding in the
interface and weakens the assembly of the dimeric state (Wang et al., 2018). Confocal
images of S48E after 4 and 18-hour inductions differ greatly. After 4 hours, cells
containing S48E show large amount of nuclear protein with diffuse cytoplasmic protein.
18-hour images show a single large aggregate overlapping, but larger in size, with the
nucleus. Though differences in aggregation tendencies are observed between wild type
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TDP-43 and S48E exist, overexpression results in similar levels of toxicity. Similar to
the results of Q331K, yeast-spotting assays performed with yeast containg wild type
TDP-43 and S48E on low copy plasmids might provide more insight on toxicity
differences.
Preliminary RNA decoy results show present a lack of “rescue” effect by decoys.
No difference in cell viability was observed. So far, live cell imaging has failed to
capture images of tagged RNAs. JPS_1481 decoys are currently being tested. Since
larger UG repeat length result in a larger affinity for TDP-43 binding, the increased
binding domain length of 12 nucleotides per binding site in JPS_1481 decoys offers
optimism for an increased propensity to co-localize with TDP-43. Based on RRM mutant
toxicity data, TDP-43 binding to RNAs drives cellular toxicity (possibly by disrupting
critical RNAs in the cytoplasm). Introducing these synthetic RNAs, containing regions
TDP-43 preferentially binds, offers hope to rescuing cells from TDP-43 toxicity without
genetic modification.
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